Estimation of SARS-CoV-2 emissions from non-symptomatic cases

1

A.A.Prof. Dr. Michael Riediker¹, Dr. Dai-Hua Tsai^{1,2} 2 3 1 Swiss Centre for Occupational and Environmental Health, Winterthur, Switzerland 2 Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of 4 5 Psychiatry Zurich, University of Zurich, Zurich, Switzerland **Key Points** 6 7 Question: How much SARS-CoV-2 virus is released from a case by breathing and coughing, 8 and what is the resulting concentration in a room? 9 Finding: Both, breathing and coughing are predicted to release large numbers of viruses, which can lead to billions of virus copies/m³ in a poorly ventilated room with a coughing 10 11 emitter. Meaning: These results may explain the high rate of transmissions and implies the need for 12 13 strict respiratory protection when people are in the same room with a COVID-19 case. Word counts: 14 Abstract: 272, Manuscript: 1801, Tables: 1, Figures: 3 15 Address for correspondence 16 17 Michael Riediker michael.riediker@alumni.ethz.ch 18 19 Swiss Centre for Occupational and Environmental Health (SCOEH) 20

Binzhofstrasse 87 CH-8404 Winterthur Switzerland Note: This preprint reports hew research that has not been certified by peer review and should not be used to guide clinical practice.

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

Abstract Importance: Cases of the coronavirus disease 2019 (COVID-19) with no or mild symptoms were reported to frequently transmit the disease even without direct contact. The severe acute respiratory syndrome virus (SARS-COV-2) was found at very high concentrations in swab and sputum of such cases. **Objective**: We aimed to estimate virus release from such cases into different aerosol sizes by normal breathing and coughing, and what exposure can result from this in a room shared with such as case. Data Sources and Model: We combined the size-distribution of exhaled breath aerosols for coughing and normal breathing with viral sputum concentrations as approximation for lung lining liquid to obtain an estimate of emitted virus levels. The resulting emission data fed a single-compartment model of airborne concentrations in a room of 50m³, the size of a small office or medical exam room. **Results**: The estimated viral load in aerosols emitted by patients while breathing normally was on average 0.34 copies/cm³ and could go up to 11.5 copies/cm³. The corresponding numbers for coughing patients were 10,900 copies/cm³ and 366,000 copies/cm³, respectively, per cough. The resulting concentrations in a room with a coughing emitter were always very high, up to 2.02*10^9 copies/m³. However, also regular breathing aerosol from high emitters was predicted to lead to several thousand copies/m³. **Conclusions and Relevance**: These very high predicted virus concentrations may provide an explanation why for COVID-19, frequent community transmissions from non-symptomatic cases and also high infection rates in medical staff in hospital settings were reported. Our

findings suggest that strict respiratory protection is needed when there is a chance to be in

the same room with a patient - whether symptomatic or not - especially if this was for a

prolonged time.

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Introduction

The novel Coronavirus disease 2019 (COVID-19), emerged in late 2019 in Wuhan, China ¹ from where it spread to the entire world. COVID-19 is caused by a novel type of Coronavirus, the severe acute respiratory syndrome virus (SARS-COV-2) ². The host-receptor for SARS-CoV-2 was found to be Angiotensin I converting enzyme 2 (ACE2), which is present in cells of the lungs and airways ³. A large number of patients hospitalized for other reasons and also an important proportion of the medical staff contracted COVID-19 4. This is remarkable given that medical professionals are trained at protecting themselves against infections. Also a series of community-transmissions were reported from cases that had no apparent symptoms, some even without direct contact 5-8. Correspondences about the viral load in samples from COVID-19 patients having no or only mild symptoms reported very high concentrations of SARS-CoV-2 in swab samples $^{8-10}$. This raised the question whether transfections could occur via the air. When coughing, humans release thousands of aerosol droplets per cubic-centimeter in the size range of 0.6 to 15 µm, with the droplet concentration increasing strongly with cough flow rate ¹¹. But also normal breathing will lead to some aerosol production, which is attributed to fluid film rupture in the respiratory bronchioles during inhalation leading to the formation of droplets that are released during exhalation ¹². The size of these droplets is mostly below 1 µm ¹³. The mode of droplet generation implies that they consist of lung lining liquid including dispersed viruses. Indeed, human volunteers exposed to virus-sized nanoparticles show nano-scaled particles in their exhaled breath ^{14,15}. Also, the described

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

size distribution of particles emitted from coughing as well as normal respiration suggests that an important proportion of them will be able to remain airborne for many hours in turbulent conditions 16. Objectives This study aimed to estimate the cumulative viral load released from COVID-19 patients with no to moderate symptoms in different aerosol sizes via respiration and coughing. We then used this information to make a risk appraisal for the situation of a high emitter that is either breathing normally or coughing in a room operated at different air exchange rates. We chose a room size that is similar to a medical examination room or an office shared by two to three people. Design and Methods Concept: The release of viruses from individual patients was modeled by first calculating the viral load per exhaled droplets formed during normal breathing and while coughing. The resulting sizedistribution provided an initial estimate of the concentration of SARS-CoV-2 virus copies released by a regularly breathing or coughing patient. This viral emission factor was then fed into a well-mixed one-compartment model to simulate the situation in a closed room with different ventilation air exchange rates. Data sources: Data on the number of viral copies present in sputum was used to estimate the SARS-CoV-2 viral load present in the lining liquid of respiratory bronchioles in patients ⁹, specifically an average of 7*10^6 copies/ml with a maximum of 2.35*10^9 copies/ml (hereafter referred to as "high emitters"), and 1,000 copies/ml representing a low-virus producing patient ("low

90 emitters").

89

91

92

93

94

95

96

97

98

100

101

102

104

105

106

107

108

109

110

Exhaled aerosol size distributions and numbers were retrieved from published studies on

coughing ¹¹ and healthy persons ¹². Both studies assessed the size-number distribution of

freshly emitted aerosols. The concentration of viral copies in each aerosol size was

calculated from the volume of the aerosols, the actual count number in each size and the

above-mentioned virus-load per ml sputum. The viral load in the actual aerosol counts in

each aerosol size was then used to calculate the total viral concentration. The cumulative

emissions in the PM₁₀ fraction were summed up after applying the standard size

fractionation curves ¹⁷ to the aerosol distribution.

99 Model:

A one-compartment model estimated the virus load concentration C for a perfectly mixed

room of volume V_R of 50 m³ with one patient as source, using the following mass-balance

(equation 1):

103
$$V_R * \frac{dC}{dt} = c_{PM10} * RR * V_t - \frac{V_R}{ER} * C(t) - \frac{\ln(2) * V_R}{t_{1/2}} * C(t)$$
 (1)

The emission rate was calculated from the concentration c_{PM10} , the viral load in the PM_{10} -size range, which are particles collected with a 50% efficiency cut-off at 10 μ m aerodynamic diameter; and a respiratory rate of 15 breaths per minute (RR) at a tidal volume of V_t of 500 ml per breath. Air exchange rates (ER) used were 1-, 3-, 10- and 20-times per hour. The virus' half-life $t_{\frac{1}{2}}$ of 1.1 hours was obtained from an experimental study about the persistence of SARS-CoV-2 on surfaces and when airborne 18 , tested by assessing the 50% tissue culture infective dose (TCID₅₀).

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

The model for coughing was identical, except that coughing was assumed to happen every 30 seconds at a volume of 250 ml. All statistics and models were calculated using Stata/SE 15.1 (Mac 64-bit Intel, Rev. 03 Feb 2020, StataCorp, College Station, TX, USA). Results Emissions from normal breathing patients To estimate the virus emissions from patients breathing normally, we first calculated the viral load for the aerosol size distribution. Figure 1 shows that the highest virus load is present in the largest aerosol size. The cumulative total emission per breath was 0.34 copies/cm³(air) for an average patient, and 11.5 copies/cm³ for high emitters. The cumulative emissions in the PM₁₀ fraction were about 1/3 of these values with 0.12 copies/cm³ (average) and 4.1 copies/cm³ (high) per breath. Emission from coughing patient We then estimated the virus emissions from a coughing patient (Figure 2). The cumulative total emission per cough was 19,400 copies/cm³ for an average patient, and 651,315 copies/cm³ for high emitters. The cumulative emissions in the PM₁₀ fraction were about 1/2 of these values with 10,900 copies/cm³ (average) and 366,000 copies/cm³ (high) per cough. Exposure estimation for bystanders To estimate the exposure of bystanders spending time in the same room as a COVID-19 positive person, we calculated the time-course of the viral load in the thoracic size fraction for aerosols released from a high-emitter either breathing normally or coughing. Figure 3 shows the results for a high-emitting patient coughing frequently.

For a typical hospital ventilation situation of 10 air exchanges per hour, the concentration plateaus after about 30 minutes, while for a typical office with 3 air exchanges/hour, concentrations continue to rise for almost three hours. In the used model, concentrations scale linearly with the patient emission rate, the plateau concentrations for different emitting patients and ventilation types are summarized in Table 1.

Discussion

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

An elevated number of viruses is expected to be released by COIVD-19 patients in the form of airborne aerosols, especially when they are coughing. While the bigger portion of the emitted viral load is in the form of large particles that can deposit rapidly, there is also an important portion in the smaller size fractions. Small aerosols can remain airborne for an extended time ¹⁶ and are very effective at reaching the deeper regions of the lungs. An average person breathes about a half m³ per hour in resting state ¹⁹, which can rapidly increase to several m³ during exercise ²⁰. Thus, a person spending time in a room with an average emitting patient breathing normally has a realistic chance of inhaling tens to hundreds of copies of the virus even when keeping distance from that person. The situation is worse in the presence of a high emitter and worst if the patient is a coughing high emitter. A review of a wide range of respiratory viruses suggests that the infective dose is often quite low. Sometimes as few as few hundred units of active virus (TCID₅₀) ²¹ seem sufficient to provoke a disease. Thus, our modelling suggests that there is a clear risk of infections for a person spending an extended time in the room with an infected person, even if the distance is too large for direct transmission. The situation is worse if the person is coughing. The very high virus load in exhaled respiratory aerosols proposed by our assessment may be an explanation why COVID-19 was associated with much more transfections to hospital staff than what was expected from SARS ⁴. While having everybody wear a surgical face mask can be an effective source control ²², the protective factors may still be insufficient if an extended amount of time is spent in the same room, especially if the room is small and the ventilation low. Increasing ventilation can help to some extent but is not sufficient in a room of the size of a typical office or medical exam room. Note also that ventilation design for hospitals is complex and not always functioning as intended ²³.

What are the implications for the normal life and the workplace?

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

- The risk of infection is real when being near an infected person in a room for more than a few minutes and this even when keeping distance to that person.
- Sharing a workplace in a small room with a non-symptomatic case seems not
 advised. This implies that workplaces should not be shared as long as there are no
 rapid tests to differentiate between healthy and non-symptomatic cases.
- Medical staff is advised to wear the best possible respiratory protection whenever in the same room as a patient, especially when this person is coughing.
- In addition, every patient, also non-symptomatic ones, should wear a well-fitting surgical face mask to reduce emissions, which will increase the overall protection for the medical staff.
- Our assessment has a number of limitations. Namely:
 - The estimated virus levels strongly depend on the number of virus copies produced by a COVID-19 case. We used sputum data from a well described peer-reviewed study ⁹ assuming that it is a reasonable approximation for the virus load in the respiratory bronchioles, the space where most respiratory aerosols are formed. Our

high-emitter estimates would be 100-fold higher if the most extreme correspondence data was used ¹⁰.

We used information about virus copies but compare the results with TCID₅₀ infective dose. Research on other virus types suggests that the number of virus copies and TCID₅₀ are comparable ²⁴. However, it would be important to confirm this relationship for the case of SARS-CoV-2.

For breath aerosols release, we used data reported for normal breathing young healthy subjects. However, aerosol formation is influenced by surface tension of the lung lining liquid ²⁵. It is likely that aerosol formation will be altered in COVID-19 positive cases but it is not clear in which direction.

Aerosol droplet will shrink in dry air ²⁶, resulting in a shift to smaller particle sizes. This will not directly change the number of copies in the PM₁₀ range but simply upconcentrate the viral load per aerosol. While we addressed passivation of viruses in the air by using the documented half-life ¹⁸, it is still possible that viruses in smaller droplets are quicker passivated because of shorter diffusion distances for airborne oxidants and faster increasing salinity. Our estimates would be slightly smaller if this was relevant.

Acknowledgments

This modelling was entirely funded by the Swiss Centre for Occupational and Environmental Health (SCOEH).

References

- 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with
- 200 Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-733.
- 201 doi:10.1056/NEJMoa2001017
- 2. Gorbalenya AE, Baker SC, Baric RS, et al. Severe Acute Respiratory Syndrome-
- 203 Related Coronavirus: The Species and Its Viruses a Statement of the Coronavirus Study
- 204 *Group*. Microbiology; 2020. doi:10.1101/2020.02.07.937862
- 3. Qi F, Qian S, Zhang S, Zhang Z. Single cell RNA sequencing of 13 human tissues
- identify cell types and receptors of human coronaviruses. *Biochem Biophys Res*
- 207 Commun. March 2020:S0006291X20305234. doi:10.1016/j.bbrc.2020.03.044
- 4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients
- 209 With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA.
- 210 2020;323(11):1061. doi:10.1001/jama.2020.1585
- 5. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of
- 212 COVID-19. *JAMA*. February 2020. doi:10.1001/jama.2020.2565
- 6. Kimball A, Hatfield KM, Arons M, et al. Asymptomatic and Presymptomatic
- 214 SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility King
- 215 County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):377-
- 216 381. doi:10.15585/mmwr.mm6913e1

7. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the 217 218 rapid dissemination of novel coronavirus (SARS-CoV2). Science. March 2020. 219 doi:10.1126/science.abb3221 220 8. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory 221 Specimens of Infected Patients. N Engl J Med. 2020;382(12):1177-1179. 222 doi:10.1056/NEJMc2001737 9. 223 Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of 224 hospitalized patients with COVID-2019. Nature. April 2020. doi:10.1038/s41586-020-2196-x 225 10. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical 226 samples. Lancet Infect Dis. 2020;20(4):411-412. doi:10.1016/S1473-3099(20)30113-4 227 228 11. Yang S, Lee GWM, Chen C-M, Wu C-C, Yu K-P. The Size and Concentration of 229 Droplets Generated by Coughing in Human Subjects. J Aerosol Med. 2007;20(4):484-494. doi:10.1089/jam.2007.0610 230 231 12. Johnson GR, Morawska L. The Mechanism of Breath Aerosol Formation. J Aerosol Med Pulm Drug Deliv. 2009;22(3):229-237. doi:10.1089/jamp.2008.0720 232 Papineni RS, Rosenthal FS. The Size Distribution of Droplets in the Exhaled 233 13. Breath of Healthy Human Subjects. J Aerosol Med. 1997;10(2):105-116. 234 235 doi:10.1089/jam.1997.10.105

236 14. Gschwind S, Graczyk H, Günther D, Riediker M. A method for the preservation and determination of welding fume nanoparticles in exhaled breath condensate. Env 237 Sci Nano. 2016;3(2):357-364. doi:10.1039/C5EN00240K 238 239 15. Sauvain J-J, Hohl MSS, Wild P, Pralong JA, Riediker M. Exhaled breath 240 condensate as a matrix for combustion-based nanoparticle exposure and health effect 241 evaluation. J Aerosol Med Pulm Drug Deliv. 2014;27(6):449-458. doi:10.1089/jamp.2013.1101 242 Willeke K, Baron PA, eds. Aerosol Measurement: Principles, Techniques, and 243 16. 244 Applications. New York: Van Nostrand Reinhold; 1993. 17. BSI. EN 481:1993 Workplace Atmospheres. Size Fraction Definitions for 245 Measurement of Airborne Particles. BSI; 1993. 246 247 18. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability 248 of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. March 249 2020:NEJMc2004973. doi:10.1056/NEJMc2004973 250 19. Beardsell I, ed. Get through MCEM. Part A: MCQs. London: RSM; 2011. 251 20. Ramos CA, Reis JF, Almeida T, Alves F, Wolterbeek HT, Almeida SM. Estimating the inhaled dose of pollutants during indoor physical activity. Sci Total Environ. 252 2015;527-528:111-118. doi:10.1016/j.scitotenv.2015.04.120 253 21. Yezli S, Otter JA. Minimum Infective Dose of the Major Human Respiratory 254 and Enteric Viruses Transmitted Through Food and the Environment. Food Environ 255 Virol. 2011;3(1):1-30. doi:10.1007/s12560-011-9056-7 256

257 22. Patel RB, Skaria SD, Mansour MM, Smaldone GC. Respiratory source control 258 using a surgical mask: An in vitro study. J Occup Environ Hyq. 2016;13(7):569-576. 259 doi:10.1080/15459624.2015.1043050 260 23. Grosskopf KR, Herstein KR. The aerodynamic behavior of respiratory aerosols 261 within a general patient room. 2012;18(4):15. 24. Kim J-O, Kim W-S, Kim S-W, et al. Development and Application of 262 263 Quantitative Detection Method for Viral Hemorrhagic Septicemia Virus (VHSV) 264 Genogroup IVa. Viruses. 2014;6(5):2204-2213. doi:10.3390/v6052204 265 25. Edwards DA, Man JC, Brand P, et al. Inhaling to mitigate exhaled bioaerosols. Proc Natl Acad Sci. 2004;101(50):17383-17388. doi:10.1073/pnas.0408159101 266 267 26. Holmgren H, Bake B, Olin A-C, Ljungström E. Relation Between Humidity and 268 Size of Exhaled Particles. J Aerosol Med Pulm Drug Deliv. 2011;24(5):253-260. doi:10.1089/jamp.2011.0880 269 270 Figure legends 271 272 Figure 1: Size distribution of exhaled aerosols (left) during normal respiration and resulting 273 viral emissions per breath (right) for average (red), high and low emitters (spike-lines) per 274 aerosol size. 275 Figure 2: Size distribution of exhaled aerosols (left) during coughing and resulting viral 276 emissions per breath (right) with average (red), high and low emitters (spike-lines) per 277 aerosol size.

278 Figure 3: Temporal course of airborne virus load in a perfectly mixed room of 50 m3 for

different air exchange rates. The emitter has a high virus-load in the lungs and is coughing

280 intermittently.

Tables

281

Table 1: Plateau concentration for different combinations of air exchange rate, emission form and emitter type.

1 / hour	3 / hour	10 / hour	20 / hour
169 minutes	77 minutes	26 minutes	14 minutes
Airborne viral concentration at plateau (copies/m³)			
0.0096	0.0043	0.0015	0.0008
44.80	20.18	6.87	3.54
22,554	10,100	3,458	1,782
859	386	132	67.9
4,010,000	1,800,000	615,000	317,000
2.02e+09	9.06e+08	3.10e+08	1.60e+08
	169 minutes Airborne v 0.0096 44.80 22,554 859 4,010,000	169 minutes 77 minutes Airborne viral concentrat 0.0096	169 minutes 77 minutes 26 minutes Airborne viral concentration at plateau 0.0096 0.0043 0.0015 44.80 20.18 6.87 22,554 10,100 3,458 859 386 132 4,010,000 1,800,000 615,000

Figure 1




Figure 2 6000 -1.0e+06 Virus load in exhaled cough [dN/dlogDp /cm³] 1.0e+04 Aerosol droplets per cough [dN/dlogD $_{
m p}$ /cm 3] 4000 1.0e+02 1.0e+00 2000 1.0e-02 20 .5 .5 $\stackrel{1}{2}$ $\stackrel{1}{5}$ 1 Aerosol size [μ m] 20 10 10 Aerosol size [µm]

